This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| General Practice Research Database | |
|---|---|
| Name | General Practice Research Database |
| Other names | GPRD |
| Country | United Kingdom |
| Established | 1987 |
| Successor | Clinical Practice Research Datalink |
General Practice Research Database
The General Practice Research Database was a longitudinal clinical database derived from United Kingdom National Health Service, collecting anonymized primary care records from participating NHS Trusts, National Health Service (England), and general practices across England, Scotland, Wales and Northern Ireland. It supported observational studies alongside institutions such as University of Manchester, London School of Hygiene and Tropical Medicine, University of Oxford and University College London, and interfaced with regulatory agencies like the Medicines and Healthcare products Regulatory Agency and European Medicines Agency.
The database originated in 1987 as a collaboration among Office of Population Censuses and Surveys, University of Manchester, and the MRC-funded initiatives tied to primary care reforms under figures associated with Margaret Thatcher-era health policy; it expanded through partnerships with entities such as the Wellcome Trust, Medical Research Council, and the British Medical Association. During the 1990s and 2000s it grew via linkage projects involving the Hospital Episode Statistics programme, the National Cancer Registration and Analysis Service, and the Office for National Statistics, and later transitioned into the Clinical Practice Research Datalink under governance by MHRA and the Department of Health and Social Care.
Records comprised coded entries using clinical classifications interoperable with systems like Read codes, linked demographic fields drawn from NHS number registers, and prescription data cross-referenced to formularies such as the British National Formulary. The dataset included diagnoses, laboratory results, immunization records, referrals, and lifestyle indicators collected from participating practices registered with bodies like the General Medical Council and aggregated under protocols influenced by standards from World Health Organization and terminologies akin to SNOMED CT. Linkage capabilities allowed combination with hospital datasets such as NHS Digital datasets, cancer registries like Public Health England collections, and mortality records maintained by the Office for National Statistics.
Access and governance frameworks involved oversight by organisations including the Medicines and Healthcare products Regulatory Agency, ethics review by committees aligned with Health Research Authority, and data custodianship shared with university partners such as University of Cambridge and King's College London. Data anonymization and disclosure control followed guidance from bodies such as the Information Commissioner's Office, with approvals modeled on processes used by the National Institute for Health and Care Excellence and linkage agreements comparable to those used by the Clinical Practice Research Datalink. Commercial and academic access required governance agreements similar to contracts negotiated with industry stakeholders including GlaxoSmithKline, AstraZeneca, and Pfizer under data-sharing arrangements analogous to those enforced in large-scale cohorts like the UK Biobank.
The resource enabled pharmacoepidemiology, vaccine safety, and health services research conducted by groups at London School of Hygiene and Tropical Medicine, Imperial College London, University of Liverpool, and international collaborators at Harvard University and Johns Hopkins University. Studies supported surveillance activities relevant to regulatory reviews by the European Medicines Agency and post-marketing safety assessments commissioned by the Food and Drug Administration in partnership with transatlantic consortia such as the International Society for Pharmacoepidemiology. The database informed clinical guidelines from organisations like National Institute for Health and Care Excellence and influenced health policy discussions within the Department of Health and Social Care and parliamentary committees including the Health Select Committee.
Validation exercises involved methodological comparisons with cohort studies such as the British Regional Heart Study and linkage validation against registries like the National Cancer Registration and Analysis Service; methodologists from University College London and University of Bristol evaluated misclassification, missingness, and coding variation relative to standards from European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Limitations included potential selection bias from participating practices accredited by entities like the Royal College of General Practitioners, heterogeneity in coding practices tied to different versions of Read codes, and challenges in outcome adjudication without direct linkage to imaging archives or primary source hospital notes as held by NHS Trusts.
High-profile studies using the resource examined associations between statins and outcomes in cardiovascular cohorts informing guidelines from NICE, vaccine safety investigations influencing recommendations by Joint Committee on Vaccination and Immunisation, and adverse drug reaction surveillance that prompted regulatory communications from the MHRA and label updates by firms including Roche and Sanofi. Large-scale pharmacoepidemiologic analyses conducted by investigators affiliated with University of Oxford and University of Edinburgh contributed evidence cited in reviews by the Cochrane Collaboration and systematic assessments used by the World Health Organization Immunization Safety Surveillance efforts.
Category:Medical databases Category:Epidemiology